WO2023239945 - BTOLOGICAL ACTIVITIES OF 5-(2-(4-(4-FLUORO-2-METHYL-1H-INDOL-5- YLOXY)-6-METHOXYQUINOLIN-7-YLOXY)ETHYL)-5-AZASPIRO[2.4]-HEPTAN- 7-OL CRYSTALLINE, PHOSPHORIC ACID SALT AND ITS ENANTIOMERS
National phase entry:
Publication Number
WO/2023/239945
Publication Date
14.12.2023
International Application No.
PCT/US2023/024993
International Filing Date
09.06.2023
Title **
[English]
BTOLOGICAL ACTIVITIES OF 5-(2-(4-(4-FLUORO-2-METHYL-1H-INDOL-5- YLOXY)-6-METHOXYQUINOLIN-7-YLOXY)ETHYL)-5-AZASPIRO[2.4]-HEPTAN- 7-OL CRYSTALLINE, PHOSPHORIC ACID SALT AND ITS ENANTIOMERS
[French]
ACTIVITÉS BIOLOGIQUES DE 5-(2-(4-(4-FLUORO-2-MÉTHYL-1H-INDOL-5-YLOXY)-6-MÉTHOXYQUINOLÉIN-7-YLOXY)ÉTHYL)-5-AZASPIRO[2.4]-HEPTAN-7-OL CRISTALLIN, SEL D'ACIDE PHOSPHORIQUE ET SES ÉNANTIOMÈRES
Applicants **
ADVENCHEN PHARMACEUTICALS, LLC
Inventors
CHEN, Guoqing, Paul
LI, Zhe
LI, Yingyin
QI, Lisha
YU, Tingting
Priority Data
63/351,205
10.06.2022
US
18/206,506
06.06.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2675 | |
| EPO | Filing, Examination, Granting | 16950 | |
| Japan | Filing, Examination, Granting | 2450 | |
| South Korea | Filing, Examination, Granting | 2631 | |
| USA | Filing, Examination, Granting | 9110 |
Total:
33,816
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
-A). Furthermore, their anti-cancer activities, stabilities, chirality, dissolutions and treatment indications have also been investigated.[French]
-A). En outre, leurs activités anticancéreuses, stabilités, chiralité, dissolutions et indications thérapeutiques ont également été étudiées.